G. Lange Louis's most recent trade in NewAmsterdam Pharma Company NV was a trade of 44,173 Ordinary Shares done at an average price of $30.4 . Disclosure was reported to the exchange on March 11, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Sale of securities on an exchange or to another person at price $ 30.41 per share. | 11 Mar 2026 | 44,173 | 10,806 | - | 30.4 | 1,343,301 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Sale of securities on an exchange or to another person at price $ 31.23 per share. | 11 Mar 2026 | 446 | 10,360 | - | 31.2 | 13,929 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | 06 Mar 2026 | 44,619 | 54,979 | - | 11.5 | 513,119 | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | 06 Mar 2026 | 44,619 | 0 | - | - | Warrant (right to buy) | ||
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Sale of securities on an exchange or to another person at price $ 29.41 per share. | 06 Mar 2026 | 28,186 | 0 | - | 29.4 | 828,950 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 15,300 | 15,300 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2026 | 3,400 | 10,360 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2025 | 68 | 28,186 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2025 | 68 | 0 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Co NV | Louis Lange G. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 69 | 28,118 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Louis Lange G. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 69 | 68 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 69 | 137 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 69 | 28,049 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 3,308 | 3,308 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 3,102 | 10,062 | - | 0 | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 3,102 | 206 | - | - | Restricted Stock Unit | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 32,500 | 32,500 | - | - | Option (right to buy) | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 6,960 | 6,960 | - | - | Ordinary Shares | |
| NewAmsterdam Pharma Co NV | Louis G. Lange | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 13 Feb 2024 | 5,000 | 24,878 | - | 19 | 95,000 | Ordinary Shares |
| NewAmsterdam Pharma Co NV | G. Lange Louis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 10,000 | 10,000 | - | - | Option (right to buy) |